Call (310) 824-6199 to schedule your consultation today
Announcing a non-surgical breakthrough for the treatment of selected patients with failed back surgery syndrome
Background:
Severe back pain due to failed back surgery
syndrome is not an uncommon condition. Up to 67% of patients undergoing
instrumented fusion surgery for chronic back pain continue to
have significant pain at 1-8 years after surgery (Bentsen, S.
B., A. K. Wahl, et al. (2007). "Outcomes for patients
with chronic low back pain treated using instrumented fusion."
Scand J Caring Sci 21(1): 71-8). Effective treatment options
after back surgery fails are limited; among the most commonly
attempted treatment options are epidural steroid injections and
pain management, usually with opioids. Each of these options is
fraught with difficulties. Epidural steroid injections, if they
are effective at all, rarely provide more than short-term relief,
are painful, and can have serious complications. Pain management
does nothing to alter the natural history of the underlying process,
and chronic use of drugs entails expense and side effects. The
molecule TNF-alpha (TNF) has been demonstrated to be centrally
involved in the causation of neuropathic pain, including the pain
which may accompany failed back surgery. Excess TNF may be addressed
by targeted administration of an anti-TNF therapeutic, a patented
new non-surgical treatment approach for selected patients with
severe chronic pain due to nerve root inflammation which was invented
at the INR, and is available exclusively at the INR
[see For Physicians and Scientists].
U.S. Patents citing an INR patent (partial list):
Amgen Fremont, Inc.
Antibodies directed to tumor necrosis factor US patent 7,285,269
Medarex, Inc., GenMab A/S, Human monoclonal antibodies
against interleukin 8 (IL-8), US patent 7,282,568
Reagents of the University of Colorado, Methods for treating
neuropathic pain by administering IL-10 polypeptides, US Pat.
7261882
Depuy Spine, Inc., Autologous coatings for implants US
Pat. 7217425
Applied Molecular Evolution TNF-alpha binding molecules,
US patent 7,101,978
Kennedy Institute of Rheumatology, Small molecular weight
TNF receptor multimeric molecule US Pat. 7070783
Schering Corp. US patent 6,838,466, Compounds for the treatment
of inflammatory disorders
Pharmacia Corporation, Methods for treating glaucoma, US
Pat. 6814966
The General Hospital Corporation Treatments for immune-mediated
ear disorders, US Pat. 6548527
U.S. patent applications citing an INR patent (partial list):
20070172449 Xencor, Inc. -
Tnf-Alpha Variant Formulations For The Treatment Of Tnf-Alpha
Related Disorders
20060289021 Johnson & Johnson - Ultraviolet Therapies
For Spine-Related Pain
20060173080 Methods of modulating TNF using bupropion
20050079178 David Kem and Eugene Patterson - Inhibitor of
cardiac tachyarrhythmias
Medtronic, Inc.
20050180974 Medtronic,
Inc. - Extracellular TNF inhibitors for treating CNS disorders
20050095246 Medtronic, Inc. -Techniques to treat
neurological disorders by attenuating the production of pro-inflammatory
mediators
DePuy Spine:
20060019869 DePuy Spine, Inc. - Intradiscal anti-inflammatory
therapy involving autologous adiponectin
20060130853 DePuy Spine, Inc. - Ultra violet therapies
for spine-related pain
20050112091 DePuy Spine, Inc. - Local intraosseous
administration of bone forming agents and anti-resorptive agents,
and devices therefor
20050038001 DePuy Spine, Inc. -Transdiscal administration
of cycline compounds
20050025765 DePuy Spine, Inc. -Trans-capsular administration
of high specificity cytokine inhibitors into orthopedic joints
20040229878 DePuy Spine, Inc. - Transdiscal administration
of specific inhibitors of P38 kinase
20040228853 DePuy Spine, Inc. - Transdiscal administration
of high affinity anti-MMP inhibitors
Note:these lists should not be construed to imply that a business or other relationship exists between these companies and the INR.
Scientific Articles:
1. Uceyler N, Sommer C. Cytokine-induced Pain: Basic Science
and Clinical Implications. Reviews in Analgesia 2007;9(2):87-103.
2. Tweedie D, Sambamurti K, Greig NH. Drug Design & Development
Section, Laboratory of Neurosciences, Intramural Research Program,
National Institute on Aging, National Institutes of Health, Baltimore,
MD 21224, US. TNF-alpha Inhibition as a Treatment Strategy
for Neurodegenerative Disorders: New Drug Candidates and Targets.
Curr Alzheimer Res. 2007 Sep;4(4):375-8.
2. Tubbs RS, Hansasuta A, Loukas M, Louis RG, Jr., Shoja MM, Salter
EG, et al. The basilar venous plexus. Clin Anat 2007.
3. Saxena AK, Kumar S. Management strategies for pain in breast
carcinoma patients: current opinions and future perspectives.
Pain Pract 2007;7(2):163-77.
4. Owlia MB, Salimzadeh A, Alishiri G, Haghighi A. Comparison
of two doses of corticosteroid in epidural steroid injection for
lumbar radicular pain. Singapore Med J 2007;48(3):241-5.
5. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara
LK, et al. A novel p38alpha MAPK inhibitor suppresses brain
proinflammatory cytokine up-regulation and attenuates synaptic
dysfunction and behavioral deficits in an Alzheimer's disease
mouse model. J Neuroinflammation 2007;4(1):21.
6. Hu W, Ranaivo HR, Roy SM, Behanna HA, Wing LK, Munoz L, et
al. Development of a novel therapeutic suppressor of brain
proinflammatory cytokine up-regulation that attenuates synaptic
dysfunction and behavioral deficits. Bioorg Med Chem Lett
2007;17(2):414-8.
7. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine
expression in degenerate and herniated human intervertebral discs:
IL-1beta and TNFalpha expression profile. Arthritis Res Ther.
2007 Aug 9;9(4):R77.
Hardcover/ Bound Texts:
1. Neuroinflammation in Neuronal Death and Repair, Volume
82 (International Review of Neurobiology.) G. Bagetta, editor
(Hardcover - Jul 16, 2007) Amsterdam ; Boston : Elsevier Academic
Press ©2007. ISBN: 9780123739896 0123739896.
2. Interactions Between Neurons and Glia in Aging and Disease
by Joao Malva, Ana Cristina Rego, Rodrigo Cunha, and Catarina
Oliveira (Eds.) (Hardcover - Aug 22, 2007). 2007, Approx. 535
p., Hardcover ISBN: 978-0-387-70829-4 New York ; London : Springer,
2007.
3. Cytokines in the Genesis and Treatment of Cancer (Cancer
Drug Discovery and Development) by Michael A. Caligiuri and Michael
T. Lotze (Hardcover - April 20, 2007) Totowa, N.J. : Humana Press
©2007. ISBN: 9780896038202 0896038203 9781597454551 1597454559.
4. Chapter 10: Anti-TNF-alpha antibody and cancer cachexia,
The ASCRS Textbook of Colon and Rectal Surgery by J.M. Church,
J. Garcia-Aguilar, P.L. Roberts, and T.J. Saclarides; New York
: Springer ©2007. ISBN: 9780387248462 0387248463.
5. Spinal Reconstruction: Clinical Examples of Applied Basic
Science, Biomechanics and Engineering by Kai-Uwe Lewandrowski,
Michael J. Yaszemski, Iain Kalfas, and Paul Park (Hardcover -
Feb 12, 2007) New York : Informa Healthcare ©2007. ISBN:
9780849398155 0849398150.
6. Olesen J, Jensen T. From Basic Pain Mechanisms to Headache.
Oxford University Press 2007.
7. Neuroimmunology: The Immune System and Alzheimers, in
the 2007 Progress Report on Brain Research, Dana Alliance for
Brain Initiatives, Dana Press, New York ©2007.
Links
Failed Back Surgery Syndrome, in Wikipedia
